Langer C - Search Results

1

Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma.

Weiss JM, Bagley S, Hwang WT, Bauml J, Olson JG, Cohen RB, Hayes DN, Langer C. Weiss JM, et al. Among authors: langer c. Cancer. 2016 Aug 1;122(15):2350-5. doi: 10.1002/cncr.30067. Epub 2016 May 19. Cancer. 2016. PMID: 27197056 Free article.

2

Thymic hyperplasia with hemorrhage simulating recurrent Hodgkin disease after chemotherapy-induced complete remission.

Langer CJ, Keller SM, Erner SM. Langer CJ, et al. Cancer. 1992 Oct 15;70(8):2082-6. doi: 10.1002/1097-0142(19921015)70:8<2082::aid-cncr2820700812>3.0.co;2-6. Cancer. 1992. PMID: 1382826 Review.

3

Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer.

O'Dwyer PJ, Langer CJ, Walczak J, Levy MH, Padavic-Shaller K, Hudes GR, Litwin S, Comis RL. O'Dwyer PJ, et al. Among authors: langer cj. Eur J Cancer. 1991;27(12):1589-93. doi: 10.1016/0277-5379(91)90420-i. Eur J Cancer. 1991. PMID: 1664216

4

Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma.

Langer CJ, Catalano R, Weiner LM, Scher R, Bagchi P, Saren B, Comis RL. Langer CJ, et al. Cancer Invest. 1995;13(2):150-9. doi: 10.3109/07357909509011684. Cancer Invest. 1995. PMID: 7874568 Clinical Trial.

5

Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach.

Langer CJ, Rosenblum N, Hogan M, Nash S, Bagchi P, LaCreta FP, Catalano R, Comis RL, O'Dwyer PJ. Langer CJ, et al. Cancer Chemother Pharmacol. 1993;32(3):204-8. doi: 10.1007/BF00685836. Cancer Chemother Pharmacol. 1993. PMID: 8500225

6

Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation.

Langer CJ, Curran WJ, Keller SM, Catalano RB, Litwin S, Blankstein KB, Haas N, Campli SN, Comis RL. Langer CJ, et al. Cancer J Sci Am. 1996 Mar-Apr;2(2):99-105. Cancer J Sci Am. 1996. PMID: 9166507 Clinical Trial.

7

Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.

Langer CJ, Schaebler D, Sauter E, DeMaria D, Johnson C, Reilly DM, Clark J, Leighton J, Aks C, Litwin S, Ridge JA. Langer CJ, et al. Head Neck. 1998 Aug;20(5):385-91. doi: 10.1002/(sici)1097-0347(199808)20:5<385::aid-hed5>3.0.co;2-u. Head Neck. 1998. PMID: 9663665 Clinical Trial.

8

Pretreatment p53 protein expression correlates with decreased survival in patients with end-stage head and neck cancer.

Sauter ER, Ridge JA, Litwin S, Langer CJ. Sauter ER, et al. Among authors: langer cj. Clin Cancer Res. 1995 Nov;1(11):1407-12. Clin Cancer Res. 1995. PMID: 9815938 Clinical Trial.

9

Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.

Schilder RJ, Goldberg M, Millenson MM, Movsas B, Rogatko A, Rogers B, Langer CJ. Schilder RJ, et al. Among authors: langer cj. Lung Cancer. 2000 Jan;27(1):37-45. doi: 10.1016/s0169-5002(99)00091-4. Lung Cancer. 2000. PMID: 10672782 Clinical Trial.

10

Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC).

Langer CJ, McAleer CA, Bonjo CA, Litwin S, Millenson M, Kosierowski R, Blankstein K, Alexander R, Ozols RF. Langer CJ, et al. Eur J Cancer. 2000 Jan;36(2):183-93. doi: 10.1016/s0959-8049(99)00248-8. Eur J Cancer. 2000. PMID: 10741276 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

888 results

Search Page

Filters